Biopsy-Proven Acute Interstitial Nephritis Associated with Immune Checkpoint Inhibitors: A Systematic Review of Clinicopathologic Features, Management, and Outcomes (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #SA-PO0312; Pres time: Oct 24, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Nivolumab and pembrolizumab were the most commonly implicated ICIs, and lung adenocarcinoma and melanoma were the predominant underlying malignancies. Early recognition, kidney biopsy confirmation, and timely corticosteroid therapy are associated with improved renal recovery outcomes. Further prospective studies and standardized reporting are required to optimize management strategies."
Biopsy • Checkpoint inhibition • Clinical • Review • Acute Kidney Injury • Lung Adenocarcinoma • Lung Cancer • Melanoma • Nephrology • Non Small Cell Lung Cancer • Oncology • Renal Disease • Solid Tumor
|
|
Sai Raghavendra Prasad; Aarushi Ahuja; Piyush Ratan; Richa N. Rana; Sandeep Gopinath Huilgol; Jay Jayantilal Nagda; Archita .; Karthik Kanna Venkatesh; Urvija Padmini Kunapareddy; Vasunthra Sundaravadivelu; Shreya Agrawal; Jhanvi Agarwal; Shambhavi Priya
|